|Articles|April 1, 2006

Pharmacy Times

  • Volume 0
  • 0

Pancreatic Cancer Trials Offer Positive Results

Data from phase 3 clinical trials on theuse of Virulizin for treating pancreaticcancer revealed a significant survival benefitfor a particular subgroup of patients.The randomized, double-blind, multicentertrial compared Virulizin plus gemcitabinewith placebo plus gemcitabine inchemo-naive patients with locally advancedor metastatic pancreatic cancer.As a first-line treatment, Virulizin did notshow any statistical significance in overallsurvival, but it showed encouraging survivalrates among patients with metastasisand patients with low EasternCooperative Oncology Group performancestatus. A more recent data analysisshowed increased survival benefit forpatients taking Virulizin who received theoptional second-line therapy after diseaseprogression. At this stage, patientswho remained on Virulizin had a mediansurvival of 10.9 months, compared with7.4 months for patients taking placebo.

The results were presented onFebruary 1, 2006, at the 17th InternationalCongress on Anti-Cancer Treatment inParis, France. Jim Wright, PhD, chief executiveofficer of the drug's manufacturer,Lorus Therapeutics Inc, noted: "Virulizinsignificantly improved survival in pancreaticcancer patients who remained in thetreatment arm even when treatment withthe standard-of-care chemotherapy gemcitabinewas no longer effective. Althoughthis finding is from exploratory analysis, itprovides important new information.

Ms. Farley is a freelance medicalwriter based in Wakefield, RI.

Articles in this issue

over 19 years ago

Pharmacists—Cops or Not? (Part 2)

over 19 years ago

canyouREADtheseRxs?

over 19 years ago

compoundingHOTLINE

over 19 years ago

NSAIDs and Antihypertensive Agents

over 19 years ago

FDA Approves New Constipation Drug

over 19 years ago

Angina Drug Approved

over 19 years ago

Compounding for Vaginal Conditions

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME